Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an...

Keywords

MedicinePembrolizumabTolerabilityInternal medicineHead and neck squamous-cell carcinomaOncologyResponse Evaluation Criteria in Solid TumorsAdverse effectHead and neck cancerPopulationPhases of clinical researchClinical trialSurgeryCancerImmunotherapy

Affiliated Institutions

Related Publications

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Rita Nanda , Laura Q.M. Chow , Elizabeth Claire Dees +9 more

Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negativ...

2016 Journal of Clinical Oncology 1427 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

2016 New England Journal of Medicine 9645 citations

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid , Sylvia Adams , Hope S. Rugo +15 more

Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and t...

2018 New England Journal of Medicine 4116 citations

Publication Info

Year: 2016
Type: article
Volume: 17
Issue: 7
Pages: 956-965
Citations: 1684
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1684

OpenAlex

Cite This

APA Style

                            
                                
                                    Tanguy Y. Seiwert, 
                                
                                    Barbara Burtness, 
                                
                                    Ranee Mehra
                                
                                et al.
                            
                            (2016). 
                            Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. 
                            The Lancet Oncology
                            , 17
                            (7)
                            , 956-965.
                            https://doi.org/10.1016/s1470-2045(16)30066-3
                        

Identifiers

DOI: 10.1016/s1470-2045(16)30066-3